TransMedics Group, Inc. (BMV:TMDX)

Market Cap	41.30B -35.0%
Revenue (ttm)	11.46B +30.2%
Net Income	3.10B +251.2%
EPS	80.46 +216.8%
Shares Out	n/a
PE Ratio	13.32
Forward PE	31.60
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53
Average Volume	306
Open	1,150.00
Previous Close	n/a
Day's Range	1,150.00 - 1,189.50
52-Week Range	1,050.00 - 2,662.00
Beta	n/a
RSI	33.01
Earnings Date	May 5, 2026

About TransMedics Group

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung tra...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1998
• Employees: 898
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: TMDX

Financial Performance

In 2025, TransMedics Group's revenue was $605.49 million, an increase of 37.13% compared to the previous year's $441.54 million. Earnings were $190.29 million, an increase of 436.58%.

Financial numbers in USD